CPhI News

Purolite and Repligen have extended their existing ligand partnership through 2032.

Lonza has launched a new capsule to deliver acid-sensitive APIs to the intestine.

FDA has accepted Ashland’s Viatel bioresorbable mPEG-PDLLA pharmaceutical excipient into the FDA Novel Excipient Review Pilot Program.

Gerresheimer has developed a new dropper insert for ophthalmic formulations that it is showcasing at CPHI 2022 in Frankfurt, Germany.

Thermo Fisher Experts will demonstrate its various capabilities at CPHI Frankfurt 2022.

Roquette has launched excipients PEARLITOL CR-H and PEARLITOL 200 GT.

The CPHI Annual Report 2022 predicts cash reserves from venture capitalists and private equities will drive expansion in the demand for contract research organizations and contract development and research organizations.

Pharma supply chains are no longer hidden beyond the reach of ESG agendas, making it important for companies to accelerate adoption of new manufacturing processes and environmental technology

The latest CPHI report has been published, predicting that a significant shift in outsourcing strategies is being experienced globally.

The second part of the CPhI Annual Report has predicted an accelerated rate of change in pharma manufacturing and supply over the coming five years.

The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.

The first part of the 2021 CPhI Annual Report has been published and predicts a strong outlook for CDMOs over the next few years.

Executives that participated in the CPhI post-pandemic survey are predicting a push for repatriation of manufacturing globally.

CPhI’s post-pandemic report predicts strong progression in pharma innovation, with breakthroughs in multi-modal disease therapies, a transformative effect of mRNA platforms, and significant growth in contract services.

CPhI China event organizers are encouraged by the success of the recent event and claim that it demonstrates a reassuring return to form for pharma events in 2021, which will also fuel a boom for the industry.

The CPhI event, which was originally scheduled for Aug. 31–Sept. 2, 2021 at the Fiera Milano in Milan, Italy, will be rescheduled for Nov. 9–11, 2021 at the same venue.

Analysis from the CPhI Annual Report has revealed that the global contract services sector is benefitting from a switch toward COVID-19 manufacturing and clinical-stage contracts; however, mega-cap pharma innovation is slowing outsourcing.

The third part of the CPhI annual report has predicted a significant amount of pressure will be placed on bioprocessing networks should COVID-19 biologics gain approval.

The judges chose Sheng from a shortlist of seven candidates and highlighted his work in the Taiwanese and global markets while guiding the company through “pivotal changes” that demonstrated his abilities as a “top CEO.”

The winners were announced during day seven of CPhI Festival of Pharma.

A complete listing of event dates for CPhI and Pharmapack Europe 2021 has been released.

CPhI has launched the first part of its Annual Report.

CPhI has released the agenda for its forthcoming two-week virtual event, CPhI Festival of Pharma.

Following a review, CPhI Japan has been postponed until April 14–16, 2021 to ensure positive business conditions and greater attendance.

As a result of disruptions caused by COVID-19, CPhI Worldwide 2020 in-person event will not be taking place in Milan, Italy, but instead will be a unique digital experience to connect the global pharma industry.

CPhI Worldwide have announced that the 2020 event will be organized in accordance with new global biosafety measures, Informa’s AllSecure health and safety standard, to ensure hygiene and safety of event attendees.

The CPhI event, which was originally scheduled for May 5–7, 2020 at the Pennsylvania Convention Center in Philadelphia, PA, will be rescheduled for Sept. 9–11, 2020 at the same venue.

Ongoing coronavirus outbreak prompts date change to ensure safety of trade show participants.